MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MDP - CA58410Q2036 - Common Stock
2.66 CAD
0 (0%)
MDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of MDP get a neutral evaluation. Nothing too spectacular is happening here. MDP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year MDP was profitable.
MDP had a positive operating cash flow in the past year.
In multiple years MDP reported negative net income over the last 5 years.
In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a decent Return On Assets value of 0.25%, MDP is doing good in the industry, outperforming 66.67% of the companies in the same industry.
With a decent Return On Equity value of 0.73%, MDP is doing good in the industry, outperforming 70.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.79%, MDP belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MDP is in line with the industry average of 8.14%.
The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(5.79%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROIC | 5.79% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
MDP has a Profit Margin of 0.37%. This is in the better half of the industry: MDP outperforms 66.67% of its industry peers.
MDP has a Operating Margin of 5.76%. This is in the better half of the industry: MDP outperforms 73.33% of its industry peers.
With an excellent Gross Margin value of 53.01%, MDP belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
MDP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MDP has more shares outstanding
Compared to 1 year ago, MDP has an improved debt to assets ratio.
2.2 Solvency
MDP has an Altman-Z score of 0.54. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
MDP has a Altman-Z score (0.54) which is in line with its industry peers.
The Debt to FCF ratio of MDP is 1.57, which is an excellent value as it means it would take MDP, only 1.57 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.57, MDP belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
MDP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, MDP belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Altman-Z | 0.54 |
ROIC/WACC0.63
WACC9.17%
2.3 Liquidity
MDP has a Current Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.83, MDP is doing worse than 93.33% of the companies in the same industry.
MDP has a Quick Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.38, MDP is doing worse than 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 |
3. Growth
3.1 Past
MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.89%.
MDP shows a decrease in Revenue. In the last year, the revenue decreased by -0.63%.
MDP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.82% yearly.
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
3.2 Future
MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
MDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.06% yearly.
EPS Next Y-169.44%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue Next Year-7.83%
Revenue Next 2Y3.01%
Revenue Next 3Y3.1%
Revenue Next 5Y10.06%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 266.00, which means the current valuation is very expensive for MDP.
Based on the Price/Earnings ratio, MDP is valued a bit cheaper than 66.67% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.39, MDP is valued quite expensively.
The Price/Forward Earnings ratio is 9.55, which indicates a very decent valuation of MDP.
83.33% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
MDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 266 | ||
| Fwd PE | 9.55 |
4.2 Price Multiples
90.00% of the companies in the same industry are more expensive than MDP, based on the Enterprise Value to EBITDA ratio.
96.67% of the companies in the same industry are more expensive than MDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.65 | ||
| EV/EBITDA | 4.93 |
4.3 Compensation for Growth
The decent profitability rating of MDP may justify a higher PE ratio.
A more expensive valuation may be justified as MDP's earnings are expected to grow with 77.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y77.1%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MDP (12/19/2025, 7:00:00 PM)
2.66
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.19%
Inst Owner ChangeN/A
Ins Owners7.52%
Ins Owner ChangeN/A
Market Cap86.24M
Revenue(TTM)104.10M
Net Income(TTM)381.00K
Analysts82.22
Price Target6.3 (136.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.5%
Min EPS beat(2)0.99%
Max EPS beat(2)144%
EPS beat(4)4
Avg EPS beat(4)68.3%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)6
Avg EPS beat(8)45.18%
EPS beat(12)9
Avg EPS beat(12)92.45%
EPS beat(16)11
Avg EPS beat(16)68.92%
Revenue beat(2)0
Avg Revenue beat(2)-2.42%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.53%
Revenue beat(12)4
Avg Revenue beat(12)-1.12%
Revenue beat(16)8
Avg Revenue beat(16)1.52%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)-500%
EPS NY rev (1m)-340%
EPS NY rev (3m)8.33%
Revenue NQ rev (1m)-1.55%
Revenue NQ rev (3m)-1.74%
Revenue NY rev (1m)-2.17%
Revenue NY rev (3m)-2.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 266 | ||
| Fwd PE | 9.55 | ||
| P/S | 0.6 | ||
| P/FCF | 4.65 | ||
| P/OCF | 3.85 | ||
| P/B | 1.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.93 |
EPS(TTM)0.01
EY0.38%
EPS(NY)0.28
Fwd EY10.47%
FCF(TTM)0.57
FCFY21.52%
OCF(TTM)0.69
OCFY25.98%
SpS4.43
BVpS2.23
TBVpS-1.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROCE | 8.05% | ||
| ROIC | 5.79% | ||
| ROICexc | 6.63% | ||
| ROICexgc | N/A | ||
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% | ||
| FCFM | 12.92% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 30.83% | ||
| Cap/Sales | 2.68% | ||
| Interest Coverage | 1.96 | ||
| Cash Conversion | 107.99% | ||
| Profit Quality | 3530.97% | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 | ||
| Altman-Z | 0.54 |
F-Score5
WACC9.17%
ROIC/WACC0.63
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
EPS Next Y-169.44%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
Revenue Next Year-7.83%
Revenue Next 2Y3.01%
Revenue Next 3Y3.1%
Revenue Next 5Y10.06%
EBIT growth 1Y-53.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.19%
EBIT Next 3Y49.14%
EBIT Next 5Y51.32%
FCF growth 1Y3.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.81%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MDP.CA.
Can you provide the valuation status for MEDEXUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 6 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.